HeartFlow closes $240m Series E

HeartFlow said today it closed a $240 million Series E round of financing, with funds slated to support commercial expansion and studies of its HeartFlow FFRct analysis system. Redwood City, Calif.-based HeartFlow’s FFRct technology works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing the changes in flow across coronary lesions. Financing in the round included investments from Wellington Management, Baillie Gifford & Company and existing investors, the company said. “We are delighted to be investing in HeartFlow on behalf of our clients. Heart disease is the leading cause of death globally, in part owing to the difficulties around diagnosis. The HeartFlow Analysis improves patient experience and outcomes, whilst also reducing costs for overstretched healthcare systems — a dual objective that many healthcare companies strive for but few achieve. The underlying technology developed by HeartFlow also has the potential for broader applications for heart disease and other conditions. The capital raised here will enable HeartFlow to push forward with commercialization and invest for long-term success by continuing to advance the ways in which it can help patients and physicians,” Baillie Gifford & Company investment manager Peter Singlehurst said in a prepared statement. Funds from the round will support ramped up commercial expansion of the HeartFlow FFRct analysis system,...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Funding Roundup HeartFlow Source Type: news